- Report
- June 2025
- 26 Pages
Mexico
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 28 Pages
Brazil
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 31 Pages
United Kingdom
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 27 Pages
Russia
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 27 Pages
Spain
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 27 Pages
Italy
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 29 Pages
France
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 27 Pages
South Korea
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 27 Pages
Japan
From €4402EUR$4,995USD£3,831GBP
- Report
- June 2025
- 29 Pages
China
From €4402EUR$4,995USD£3,831GBP
- Report
- April 2024
- 132 Pages
Global
From €837EUR$950USD£729GBP
The Cardiac Marker Testing market is a subset of the Laboratory Testing market, which focuses on the diagnosis and monitoring of cardiac diseases. Cardiac markers are proteins or enzymes released into the bloodstream in response to cardiac injury or stress. These markers can be used to diagnose and monitor a variety of cardiac conditions, such as myocardial infarction, congestive heart failure, and arrhythmias. Cardiac marker testing is typically performed using immunoassay techniques, such as ELISA, CLIA, and chemiluminescence.
Cardiac marker testing is an important tool for the diagnosis and management of cardiac diseases, and is used in both clinical and research settings. It is also used to monitor the effectiveness of treatments and to assess the risk of future cardiac events.
Companies in the Cardiac Marker Testing market include Abbott Laboratories, Beckman Coulter, Siemens Healthineers, Roche Diagnostics, and Ortho Clinical Diagnostics. Show Less Read more